Sana Biotechnology, Inc. announced that Brian Piper will serve as Executive Vice President and Chief Financial Officer, effective February 17, 2026. Piper joins the company’s senior leadership team after a career that has included senior finance roles at several biotechnology firms, positioning him to strengthen Sana’s financial planning, investor relations, and capital‑raising capabilities as the company advances its metabolic disease pipeline.
Piper’s appointment comes at a pivotal moment for Sana, which has recently pivoted its focus to type‑1 diabetes and in‑vivo cell engineering. The company’s pipeline now centers on engineered cell therapies for type‑1 diabetes and B‑cell mediated autoimmune diseases, with early clinical data expected for SC451 and SG293 within the next 12 to 18 months. By bringing in an experienced CFO, Sana aims to manage the financial demands of these clinical milestones and prepare for future financing rounds.
Steve Harr, President and CEO, said, "Over the next 12-18 months, we expect to generate initial clinical data for SC451 in the treatment of type 1 diabetes and SG293 in a B-cell related disease, helping us better understand these therapies and creating important value inflection points for the company." Piper added, "I look forward to working closely with the team to ensure a strong balance sheet, drive operational excellence, and apply disciplined capital allocation in support of our vision for patient impact and shareholder value."
Sana is a clinical‑stage company with no current revenue and significant net losses, a typical profile for firms at this stage. The company has raised more than $700 million in initial financing in 2020 and an additional $133.2 million in equity financing during 2025, extending its cash runway into late 2026. The new CFO will play a key role in maintaining liquidity, managing capital expenditures, and structuring future capital‑raising efforts to support the company’s clinical development program.
The appointment signals Sana’s commitment to disciplined financial stewardship as it navigates the high costs of clinical development and the need for additional capital to reach regulatory milestones. With a focus on a narrow therapeutic area and a clear pipeline roadmap, the CFO’s expertise is expected to enhance investor confidence and support the company’s long‑term growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.